Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers

High blood pressure (HBP) is a prevalent and chronic disease, requiring pharmacologic and nonpharmacologic sustainable treatment to achieve control. "Persistence" is the continuity of pharmacological treatments. Knowing the persistence of antihypertensive therapy groups could help prioriti...

Descripción completa

Detalles Bibliográficos
Autores principales: Waisman, Gabriel Darío, Garfi, Leonardo Guillermo, Izbizky, Gustavo Hernán, Tortellá, Juan José
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2012
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/20883
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
id I10-R327-article-20883
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-327
container_title_str Revista de la Facultad de Ciencias Médicas de Córdoba
language Español
format Artículo revista
author Waisman, Gabriel Darío
Garfi, Leonardo Guillermo
Izbizky, Gustavo Hernán
Tortellá, Juan José
spellingShingle Waisman, Gabriel Darío
Garfi, Leonardo Guillermo
Izbizky, Gustavo Hernán
Tortellá, Juan José
Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
author_facet Waisman, Gabriel Darío
Garfi, Leonardo Guillermo
Izbizky, Gustavo Hernán
Tortellá, Juan José
author_sort Waisman, Gabriel Darío
title Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
title_short Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
title_full Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
title_fullStr Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
title_full_unstemmed Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
title_sort persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers
description High blood pressure (HBP) is a prevalent and chronic disease, requiring pharmacologic and nonpharmacologic sustainable treatment to achieve control. "Persistence" is the continuity of pharmacological treatments. Knowing the persistence of antihypertensive therapy groups could help prioritize those with better results. The aim is to describe the persistence to antihypertensive therapy in a cohort of patients using different methods and compare the persistence of different pharmacological groups used for hypertension treatment.Materials and MethodsObservational, retrospective cohort using secondary databases obtained during drug dispensing and electronic hospital records from the Hospital Italiano de Buenos Aires. Adult population with diagnosed hypertension and monitoring for two years.ResultsDiuretics, beta-blockers and first generation of angiotensin converting enzyme are the groups with the largest fall in persistence. Angiotensin antagonists in monotherapy or in combination with beta-blockers and diuretic second generation showed the best results of persistence. Persistence never reached 60% at 2 years.ConclusionDespite having measure persistence through different methods the results were similar and showed low persistence to antihypertensive therapy. We found no pharmacological extra variables that could explain the persistence in different therapeutic groups.
publisher Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2012
url https://revistas.unc.edu.ar/index.php/med/article/view/20883
work_keys_str_mv AT waismangabrieldario persistenceindrugtherapyofhypertensionamongdifferenttreatmentgroupsandcomparisonbetweenfixeddosecombinationsofaraiicalciumchannelblockersvsaceinhibitorscalciumchannelblockers
AT garfileonardoguillermo persistenceindrugtherapyofhypertensionamongdifferenttreatmentgroupsandcomparisonbetweenfixeddosecombinationsofaraiicalciumchannelblockersvsaceinhibitorscalciumchannelblockers
AT izbizkygustavohernan persistenceindrugtherapyofhypertensionamongdifferenttreatmentgroupsandcomparisonbetweenfixeddosecombinationsofaraiicalciumchannelblockersvsaceinhibitorscalciumchannelblockers
AT tortellajuanjose persistenceindrugtherapyofhypertensionamongdifferenttreatmentgroupsandcomparisonbetweenfixeddosecombinationsofaraiicalciumchannelblockersvsaceinhibitorscalciumchannelblockers
AT waismangabrieldario persistenciaeneltratamientofarmacologicodelahipertensionarterialentrediferentesgruposterapeuticosycomparacionentrecombinacionesadosisfijasdearaiibloqueantescalcicosvsiecabloqueantescalcicos
AT garfileonardoguillermo persistenciaeneltratamientofarmacologicodelahipertensionarterialentrediferentesgruposterapeuticosycomparacionentrecombinacionesadosisfijasdearaiibloqueantescalcicosvsiecabloqueantescalcicos
AT izbizkygustavohernan persistenciaeneltratamientofarmacologicodelahipertensionarterialentrediferentesgruposterapeuticosycomparacionentrecombinacionesadosisfijasdearaiibloqueantescalcicosvsiecabloqueantescalcicos
AT tortellajuanjose persistenciaeneltratamientofarmacologicodelahipertensionarterialentrediferentesgruposterapeuticosycomparacionentrecombinacionesadosisfijasdearaiibloqueantescalcicosvsiecabloqueantescalcicos
first_indexed 2024-09-03T20:59:32Z
last_indexed 2024-09-03T20:59:32Z
_version_ 1809210065094180864
spelling I10-R327-article-208832024-08-27T18:22:27Z Persistence in drug therapy of hypertension among different treatment groups and comparison between fixed-dose combinations of ara ii + calcium channel blockers vs ace inhibitors + calcium channel blockers Persistencia en el tratamiento farmacológico de la hipertensión arterial entre diferentes grupos terapéuticos y comparación entre combinaciones a dosis fijas de ara ii + bloqueantes cálcicos vs. ieca + bloqueantes cálcicos Waisman, Gabriel Darío Garfi, Leonardo Guillermo Izbizky, Gustavo Hernán Tortellá, Juan José High blood pressure (HBP) is a prevalent and chronic disease, requiring pharmacologic and nonpharmacologic sustainable treatment to achieve control. "Persistence" is the continuity of pharmacological treatments. Knowing the persistence of antihypertensive therapy groups could help prioritize those with better results. The aim is to describe the persistence to antihypertensive therapy in a cohort of patients using different methods and compare the persistence of different pharmacological groups used for hypertension treatment.Materials and MethodsObservational, retrospective cohort using secondary databases obtained during drug dispensing and electronic hospital records from the Hospital Italiano de Buenos Aires. Adult population with diagnosed hypertension and monitoring for two years.ResultsDiuretics, beta-blockers and first generation of angiotensin converting enzyme are the groups with the largest fall in persistence. Angiotensin antagonists in monotherapy or in combination with beta-blockers and diuretic second generation showed the best results of persistence. Persistence never reached 60% at 2 years.ConclusionDespite having measure persistence through different methods the results were similar and showed low persistence to antihypertensive therapy. We found no pharmacological extra variables that could explain the persistence in different therapeutic groups. La hipertensión arterial (HTA) es una enfermedad crónica, y prevalente, que requiere un tratamiento sostenido en el tiempo donde existen medidas farmacológicas y no farmacológicas para su control. La “persistencia” es la continuidad de los tratamientos farmacológicos. Conocer cual es la persistencia de los diferentes grupos terapéuticos antihipertensivos podría ayudar a priorizar aquellos con mejores resultados. El objetivo es describir la persistencia al tratamiento antihipertensivo en una cohorte de pacientes utilizando diferentes métodos y comparar la persistencia en los diferentes grupos farmacológicos utilizados para el tratamiento de la HTA.Materiales y MétodosEstudio observacional, de cohorte retrospectiva utilizando bases de datos secundarias obtenidas durante la dispensación de medicamentos y de los registros hospitalarios electrónicos del Hospital Italiano de Buenos Aires. Población adulta con diagnóstico de HTA y seguimiento por 2 años. ResultadosLos diuréticos, betabloqueantes de primera generación e inhibidores de la enzima convertidora de angiotensina son los grupos con la caída más importante en la persistencia. Los antagonistas de la angiotensina en monoterapia o junto con diurético y los betabloqueantes de segunda generación demostraron los mejores resultados de persistencia. La persistencia nunca llegó al 60% de los pacientes tratados a los 2 años.ConclusiónPese a haber realizado la medición de la persistencia a través de distintos métodos los resultados fueron similares y demostraron una baja persistencia al tratamiento antihipertensivo. No encontramos variables extra farmacológicas que pudieran explicar la diferente persistencia en los diferentes grupos terapéuticos. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2012-12-10 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/20883 10.31053/1853.0605.v69.n4.20883 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 69 No. 4 (2012); 202-212 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 69 Núm. 4 (2012); 202-212 Revista da Faculdade de Ciências Médicas de Córdoba; v. 69 n. 4 (2012); 202-212 1853-0605 0014-6722 10.31053/1853.0605.v69.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/20883/20489 Derechos de autor 2012 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares